Drug developer rattles tin for another cash dollop

MELBOURNE: Neurological diseases drug development company Actinogen Medical, capitalised at $95 million on the ASX,…
MELBOURNE: Neurological diseases drug development company Actinogen Medical, capitalised at $95 million on the ASX,…